STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #839 by analyst upside · 2026-08-13
EVMN
Evommune, Inc.
Healthcare · Market Cap $512M · P/E 0x
ANALYST PRICE TARGET
+95.3%
implied upside to consensus target
Current Price $14.12
Consensus Target $27.57
Bull Target $32.0
Bear Target $22.0
Analysts Covering 7
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
4
Hold
1
Sell
0
52-Week Low $10.47
52-Week High $33.2
YTD Return -18.4%
FUNDAMENTALS
Market Cap $512M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-11.83
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $10M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $10.47
52-Week High $33.2
Current Price $14.12
Bear Target $22.0
Bull Target $32.0
● Now $14.12 ● Target $27.57
TRADING DATA
Avg Volume 800K
YTD Return -18.4%
Analyst Count 7
Consensus Buy
Upside to Target +95.3%
Last Updated 2026-08-13

ANALYST SUMMARY

Evommune, Inc. (EVMN) is currently trading at $14.12 with a Wall Street consensus price target of $27.57, implying potential upside of 95.3% over the next 12 months. 7 analysts currently cover EVMN, with a consensus rating of Buy - 86% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $32.0, while the most cautious has a target of $22.0.

EVMN operates in the Healthcare sector with a market capitalisation of $512M. The stock is down 18.4% year-to-date and is currently trading near the lower end of its 52-week range of $10.47 – $33.2.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for EVMN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-05-26 31% win rate (48 calls)
Morgan Stanley - Reiterated
Overweight → Overweight 2026-05-11 Building track record
RBC Capital reit
Outperform → Outperform 2026-04-10 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-03-18 31% win rate (48 calls)
Clear Street ● Initiated
Buy 2026-03-18 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-02-10 31% win rate (48 calls)
Oppenheimer ● Initiated
Outperform 2026-01-22 14% win rate (7 calls)
Raymond James ● Initiated
Strong Buy 2026-01-08 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
54
out of 100
Coverage depth
16/30
Consensus clarity
16/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →